首页 | 本学科首页   官方微博 | 高级检索  
检索        

孟鲁司特治疗小儿过敏性紫癜的临床疗效分析
引用本文:廖培元,吴升华.孟鲁司特治疗小儿过敏性紫癜的临床疗效分析[J].成都医学院学报,2013(5):602-603,610.
作者姓名:廖培元  吴升华
作者单位:[1]山东省滕州市中心人民医院儿科,滕州277500 [2]南京医科大学第一附属医院儿科,南京210029
基金项目:基金项目:中国高校医学期刊临床专项资金项目(NO:11321487)
摘    要:目的探讨孟鲁司特治疗小儿过敏性紫癜(HSP)的临床疗效。方法将60例HSP患儿按照随机数字表法分为治疗组与对照组,每组30例。对照组给予常规治疗,治疗组在对照组基础上给予孟鲁司特治疗,10d为1个疗程。比较两组患儿的临床疗效及皮疹消退时间、腹部症状缓解时间及关节肿痛缓解时间,并观察不良反应发生情况。结果治疗组患儿显效率明显高于对照组,差异有统计学意义,且总有效率有高于对照组的趋势。治疗组患儿皮疹消退时间、腹痛缓解时间及关节肿痛缓解时间均显著少于对照组,差异有统计学意义。治疗期间,两组均未见明显不良反应。结论在常规治疗的基础上辅以孟鲁司特治疗小儿HSP,可迅速缓解微血管炎症及临床症状,减少肾脏损伤,其临床疗效确切,安全性较高。

关 键 词:孟鲁司特  过敏性紫癜  血管炎症  肾脏损伤

Analysis on Efficiency of Montelukast in the Treatment of Infantile Henoch-Schonlein Purpura
Authors:LIAO Pei-yuan  WU Shenghua
Institution:1. Department of Pediatrics, Tengzhou Central People ' s Hospital, Tengzhou 277500, China ; 2. Department of Pediatrics, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China )
Abstract:Objective To investigate the clinical effects of montelukast in the treatment of infantile Henoch- Schonlein purpura (HSP). Methods Sixty children with HSP were randomly divided into treatment group and control group, 30 cases in each group. The children in control group were given routine treatment, while those in the treatment group were added montelukast based on the routine treatment. The treatment lasted for 10 days. The clinical effects, time of rash disappearance, abdominal symptomatic remission,joint swelling remission, and adverse effects in two groups were compared. Results The effective rate in the treatment group was significantly higher than in control group. The time of rash disappearance, abdominal symptomatic remission and joint swelling remission in the treatment group were all markedly shorter than in control group. During treatments, there were no apparent adverse reactions were observed in two groups. Conclusion Application o{ montelukast based on routine treatment in treatment of infantile HSP can quickly alleviate capillary inflammation and clinical symptoms, reduces kidney injury,and has definite clinical effects and higher safety.
Keywords:Montelukast  Henoch-Schonlein Purpura  Capillary Inflammation  Kidney Injury
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号